Masaki, Chie http://orcid.org/0000-0002-5959-6182
Sugino, Kiminori
Tanizawa, Yoshinori
Nakamura, Kenichi
Okada, Yui
Cai, Zhihong
Okamoto, Takahiro
Funding for this research was provided by:
Eli Lilly Japan K.K.
Article History
Accepted: 20 November 2022
First Online: 17 December 2022
Declarations
:
: This study was funded by Eli Lilly Japan K.K., manufacturer/licensee of selpercatinib. Eli Lilly Japan K.K. was involved in the study design, data collection, data analysis, and preparation of the manuscript.
: CM and TO have no conflicts of interest to declare. KS received honorarium for lectures from Bayer, Eisai Co., Ltd. and Eli Lilly and Company. YT, KN, YO, and ZC are employees of Eli Lilly Japan K.K. and own stocks of Eli Lilly and Company.
: Ethical review and informed consent were not required because all data in this study were de-identified and collected retrospectively.
: Not applicable.
: Not applicable.
: Restrictions apply to the availability of some or all data generated or analyzed during this study to preserve patient confidentiality or because they were used under license. The corresponding author will on request detail the restrictions and any conditions under which access to some data may be provided.
: Not applicable.
: All authors were involved in the study design and participated in the interpretation of study results, and in the drafting, critical revision, and approval of the final version of the manuscript. YT and ZC conducted the statistical analysis.